)
BioLargo (BLGO) investor relations material
BioLargo Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Portfolio approach with transformative assets in energy tech, medical, odor control, and PFAS solutions, aiming for sustainability, risk minimization, and value maximization through diversification and partnerships.
Revenue for the nine months ended September 30, 2025, was $7.1M, down 49% year-over-year, mainly due to a sharp decline in sales to Pooph Inc. and related litigation and credit loss expense.
Net loss for the nine months was $11.0M, compared to $2.6M in the prior year, driven by a $3.8M credit loss from Pooph and lower sales.
Legal action initiated to recover $3.9M from Pooph, protect IP, and address contract violations, with ongoing litigation and a countersuit.
Management expresses substantial doubt about the ability to continue as a going concern without additional capital or increased revenues.
Financial highlights
Q3 2025 revenue was $1.21M, down from $4.35M in Q3 2024; nine-month revenue fell from $14M to $7M year-over-year, primarily due to Pooph.
Net loss for Q3 2025 was $7.14M, including a $3.85M impairment charge related to Pooph; nine-month net loss per share was $(0.03).
Cash position at quarter end was $4.5M, with total assets over $9M and stockholders' equity above $3M.
SG&A expenses increased to $8.3M for the nine months, partly due to Clyra's headcount doubling and non-cash stock expenses.
Gross margin for the nine months was 46%, down from 43% in the prior year.
Outlook and guidance
Clyra Medical is preparing for late 2025 or early 2026 commercialization, with first product orders expected before year-end, targeting a $732M wound care market.
Battery technology (Cellinity) is positioned for grid-scale energy storage, with multiple MOUs signed and a future valuation target exceeding $2.5B.
PFAS solution positioned for significant market entry, with Lake Stockholm project nearing operational launch and technical breakthroughs achieved.
Management expects annual revenues for 2025 to decrease compared to 2024 due to the loss of the Pooph business; further investment capital will be needed.
Next BioLargo earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage